{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:23:45Z","timestamp":1791156225663,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Light chain monoclonal gammopathy of undetermined significance (LC-MGUS) is an asymptomatic precursor of multiple myeloma (MM) and related disorders defined by abnormal free light chain (FLC) testing. Recently, revised FLC reference intervals were proposed by the iStopMM study group. We evaluated their performance in a large population-based cohort. MGUS cases were identified from the Danish Lymphoid Cancer Research (DALY-CARE) data resource, including only individuals with Freelite FLC-measurements. Cases were classified by original and revised LC-MGUS criteria, hereby identifying cases only fulfilling original but not revised criteria (reclassified as normal). Outcomes were progression to MM or related disorders. Cumulative incidence of progression with death as competing risk was examined using Aalen-Johansen estimation. Annual progression risk was assessed using a person-years approach. In total, 360 individuals classified by original criteria, 215 by revised, while 150 (40%) were reclassified as normal. In the revised group, there were 21 (9.8%) progressions; 11 (5.1%) to MM and seven (3.3%) to AL amyloidosis. Only two individuals (1.3%) progressed in the reclassified group, none to MM or AL amyloidosis. For revised LC-MGUS, the 2- and 5-year cumulative incidence of progression was 5.8% and 8.9%, respectively, with an annual progression rate of 3%. This study validates the performance of the iStopMM revised LC-MGUS criteria in a clinical cohort. Applying the revised criteria reduced LC-MGUS diagnoses by 40% without missing cases progressing to MM or AL amyloidosis. These findings confirm the accuracy of the revised criteria and support their implementation to improve diagnostics and ensure follow-up of individuals truly at risk.<\/jats:p>","DOI":"10.1038\/s41408-026-01478-y","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:35:03Z","timestamp":1774866903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Revised criteria for light chain MGUS enhance diagnostic accuracy and risk stratification"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6878-8602","authenticated-orcid":false,"given":"L\u00e6rke Sloth","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-9330","authenticated-orcid":false,"given":"Cecilie Vels\u00f8","family":"M\u00e6ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2162-8414","authenticated-orcid":false,"given":"S\u00e6mundur","family":"R\u00f6gnvaldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2377-7886","authenticated-orcid":false,"given":"Th\u00f3rir Einarsson","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1816-8106","authenticated-orcid":false,"given":"Christian","family":"Brieghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-5336","authenticated-orcid":false,"given":"Emil","family":"Hermansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten N\u00f8rgaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-9601","authenticated-orcid":false,"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-5242","authenticated-orcid":false,"given":"Carsten Utoft","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-7476","authenticated-orcid":false,"given":"Sigur\u00f0ur Yngvi","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-3530","authenticated-orcid":false,"given":"Sigr\u00fan","family":"Thorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"1478_CR1","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1182\/blood-2011-01-270140","volume":"117","author":"N Korde","year":"2011","unstructured":"Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): Novel biological insights and development of early treatment strategies. Blood. 2011;117:5573\u201381.","journal-title":"Blood"},{"key":"1478_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood-2022-163169","volume":"140","author":"TJ Love","year":"2022","unstructured":"Love TJ, R\u00f6gnvaldsson S, Thorsteinsdottir S, Aspelund T, Reed ER, Vidarsson B, et al. Prevalence of MGUS is high in the istopmm study but the prevalence of IgA MGUS does not increase with age in the way other immunoglobulin subtypes do. Blood. 2022;140:256\u20138.","journal-title":"Blood"},{"key":"1478_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","volume":"375","author":"A Dispenzieri","year":"2010","unstructured":"Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ, Colby CL, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375:1721\u20138.","journal-title":"Lancet"},{"key":"1478_CR4","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4065\/mcp.2010.0520","volume":"85","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar SV, Kyle RA, Buadi FK. Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence. Mayo Clin Proc. 2010;85:945\u20138.","journal-title":"Mayo Clin Proc"},{"key":"1478_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ijlh.12504","volume":"38","author":"NWCJ Van De Donk","year":"2016","unstructured":"Van De Donk NWCJ, Mutis T, Poddighe PJ, Lokhorst HM, Zweegman S. Diagnosis, risk stratification and management of monoclonal gammopathy ofundetermined significance and smoldering multiple myeloma. Int J Lab Hematol.2016;38:110\u201322.","journal-title":"Int J Lab Hematol."},{"key":"1478_CR6","unstructured":"Dansk Myelomatose Studie Gruppe (DMSG). MGUS - udredning og opf\u00f8lgning af monoklonal gammopati med ubestemt signifikans. 2025.https:\/\/www.dmcg.dk\/siteassets\/kliniske-retningslinjer\/opdelt-paa-dmcg\/myelomatose\/dmsg_monoklonalgammopati_v1.0.admgodk30042025.pdf."},{"key":"1478_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","volume":"5","author":"O Landgren","year":"2019","unstructured":"Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, et al. Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma. JAMA Oncol. 2019;5:1293\u2013301.","journal-title":"JAMA Oncol"},{"key":"1478_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111:785\u20139.","journal-title":"Blood"},{"key":"1478_CR9","doi-asserted-by":"publisher","unstructured":"Shpitzer D, Cohen YC, Shragai T, Melamed G, Reiner-Benaim A, Avivi I Adopting the new iStopMM-based criteria for light-chain monoclonal gammopathy of undetermined significance: an ongoing debate. Haematologica. 2024. https:\/\/doi.org\/10.3324\/haematol.2024.286239.","DOI":"10.3324\/haematol.2024.286239"},{"key":"1478_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","volume":"48","author":"JA Katzmann","year":"2002","unstructured":"Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free \u03ba and free \u03bb immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437\u201344.","journal-title":"Clin Chem"},{"key":"1478_CR11","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/jalm\/jfaa093","volume":"5","author":"D Murray","year":"2020","unstructured":"Murray D, Dispenzieri A, Kumar S, Gill H, Vachon C, Snyder M, et al. Free light chain assay drift: potential for misdiagnosis?. J Appl Lab Med. 2020;5:1411\u20133.","journal-title":"J Appl Lab Med"},{"key":"1478_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/jalm.2019.029330","volume":"5","author":"B Rindlisbacher","year":"2020","unstructured":"Rindlisbacher B, Schild C, Egger F, Bacher VU, Pabst T, Leichtle A, et al. Serum free light chain assay: shift toward a higher \u03ba\/\u03bb ratio. J Appl Lab Med. 2020;5:114\u201325.","journal-title":"J Appl Lab Med"},{"key":"1478_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2023-188547","volume":"142","author":"T Einarsson Long","year":"2023","unstructured":"Einarsson Long T, R\u00f6gnvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Eythorsson E, Indridason O, et al. Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the Istopmm study. Blood. 2023;142:535\u2013535.","journal-title":"Blood"},{"key":"1478_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-022-00732-3","volume":"12","author":"TE Long","year":"2022","unstructured":"Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12:1\u20138.","journal-title":"Blood Cancer J"},{"key":"1478_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/jamaoncol.2025.1285","volume":"11","author":"T Einarsson Long","year":"2025","unstructured":"Einarsson Long T, Rognvaldsson S, Thorsteinsdottir S, Sverrisdottir IS, Eythorsson E, Oskarsson JT, et al. New definition of light chain monoclonal gammopathy of undetermined significance. JAMA Oncol. 2025;11:753\u201361.","journal-title":"JAMA Oncol"},{"key":"1478_CR16","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1515\/cclm-2024-1226","volume":"63","author":"X Luo","year":"2025","unstructured":"Luo X, Zhang X, Yuan X, Zhao P, Zhang W, Deng L, et al. Assessment of serum free light chain measurements in a large Chinese chronic kidney disease cohort: A multicenter real-world study. Clin Chem Lab Med. 2025;63:1757\u201365.","journal-title":"Clin Chem Lab Med"},{"key":"1478_CR17","doi-asserted-by":"publisher","unstructured":"Maeng CV, R\u00f6gnvaldsson S, Einarsson Long T, Brieghel C, Hermansen E, Niemann CU et al. Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis. Blood Cancer J. 2025;15. https:\/\/doi.org\/10.1038\/s41408-025-01289-7.","DOI":"10.1038\/s41408-025-01289-7"},{"key":"1478_CR18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir EE, Turesson I, Lund SH, Lindqvist EK, Mailankody S, Korde N, et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 2015;1:168\u201374.","journal-title":"JAMA Oncol"},{"key":"1478_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41375-019-0419-7","volume":"33","author":"G Goyal","year":"2019","unstructured":"Goyal G, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, et al. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. Leukemia. 2019;33:1273\u20137.","journal-title":"Leukemia"},{"key":"1478_CR20","doi-asserted-by":"publisher","unstructured":"Brieghel C, Werling M, M\u00f8ller Frederiksen C, Parviz M, Lacoppidan T, et al. The Danish lymphoid cancer research (DALY-CARE) data resource: the basis for developing data-driven hematology. 2025. https:\/\/doi.org\/10.2147\/CLEP.S479672.","DOI":"10.2147\/CLEP.S479672"},{"key":"1478_CR21","unstructured":"Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible Summary Tables with the gtsummary Package. ."},{"key":"1478_CR22","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham H, Averick M, Bryan J, Chang W,D\u2019L, Mcgowan A, et al. Welcome to the Tidyverse. J Open Source Softw. 2019;4:1686.","journal-title":"J Open Source Softw"},{"key":"1478_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564\u20139.","journal-title":"N Engl J Med"},{"key":"1478_CR24","doi-asserted-by":"publisher","unstructured":"Gerds TA Product-Limit Estimation for Censored Event History Analysis [R package prodlim version 2025.04.28]. CRAN: Contributed Packages 2025. https:\/\/doi.org\/10.32614\/CRAN.PACKAGE.PRODLIM.","DOI":"10.32614\/CRAN.PACKAGE.PRODLIM"},{"key":"1478_CR25","doi-asserted-by":"publisher","unstructured":"Therneau TM Survival Analysis [R package survival version 3.8-3]. CRAN: Contributed Packages 2024. https:\/\/doi.org\/10.32614\/CRAN.PACKAGE.SURVIVAL.","DOI":"10.32614\/CRAN.PACKAGE.SURVIVAL"},{"key":"1478_CR26","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/jalm\/jfad027","volume":"8","author":"K Rozenova","year":"2023","unstructured":"Rozenova K, Willrich M, Snyder M, Dasari S, Kourelis T, Rajkumar SV, et al. Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance. J Appl Lab Med. 2023;8:742\u201350.","journal-title":"J Appl Lab Med"},{"key":"1478_CR27","unstructured":"NORDCAN 2.0. https:\/\/nordcan.iarc.fr\/en\/dataviz\/tables?cancers=360&key=total&multiple_cancers=0&populations=208&sexes=2&types=0&years=2023&years_available=1943_2023&mode=population&multiple_populations=1&age_start=10&age_end=17&group_populations=0&group_cancers=0&map_view_per=countries."},{"key":"1478_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood.2024025415","volume":"145","author":"A Visram","year":"2025","unstructured":"Visram A, Larson D, Norman A, Dispenzieri A, Murray D, Kyle R, et al. Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection. Blood. 2025;145:325\u201333.","journal-title":"Blood"},{"key":"1478_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.7326\/M23-2540","volume":"177","author":"E Eythorsson","year":"2024","unstructured":"Eythorsson E, Rognvaldsson S, Thorsteinsdottir S, Long TE, Reed ER, Sigurdardottir GA, et al. Development of a multivariable model to predict the need for bone marrow sampling in persons with monoclonal gammopathy of undetermined significance: a cohort study nested in a clinical trial. Ann Intern Med. 2024;177:449\u201357.","journal-title":"Ann Intern Med"},{"key":"1478_CR30","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.2024026078","volume":"145","author":"L Bertamini","year":"2025","unstructured":"Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, et al. Serum free light chains in a racially diverse population including African Americans and populations from South Africa. Blood. 2025;145:840\u20139.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01478-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:17:07Z","timestamp":1774984627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01478-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01478-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LSA has participated in a conference supported by Alexion. CVM has participated in a conference supported by Daiichi Sankyo. SR reports honoraria for scientific talks from Johnson & Johnson and Siemens Healthineers. CB has received travel grants from AbbVie and AstraZeneca. EH reports honoraria for lectures and educational materials from Amgen, Bristol Myers Squibb, Johnson & Johnson, Pfizer, Sanofi, and Takeda, research cooperation with Bristol Myers Squibb, Johnson & Johnson, and Sanofi, participation in conferences supported by Bristol Myers Squibb, Pfizer, Roche, and Takeda, and advisory board consultancy to Johnson & Johnson, Sanofi, and Oncopeptides. CUN has received research funding from AbbVie, Johnson & Johnson, AstraZeneca, Genmab, and Octapharma, and has provided consultancy for AbbVie, BeiGene, Janssen, Roche, AstraZeneca, CSL Behring, Genmab, Takeda, Octapharma, MSD, Synamics, and Lilly. KG has received research funding from Janssen and Medac. SYK reports research funding from Amgen and Celgene; Independent Data Monitoring Committee for Jansen. ST reports honoraria for scientific talks for Abbvie, GlaxoSmithKline and Thermo Fisher Scientific, advisory board for Sanofi, travel grant from Amgen and conference participation supported by GlaxoSmithKline. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted under the approval of Danish Lymphoid Cancer Research (DALYCARE) protocol by the Danish National Ethics Committee (1804410) and Data Protection Agency (P-2020-561).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"50"}}